Loading
A phase 2 trial of DZD8586 and Venetoclax in chronic lymphocytic leukaemia, run by Dizal Pharmaceuticals, now recruiting.
A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10) is a phase 2 interventional study registered as NCT07154264 by Dizal Pharmaceuticals, with 66 participants planned, started 2025-09-22 and due to reach its primary completion in 2029-12. Interventions recorded: DZD8586 and Venetoclax.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares DZD8586, Dizal Pharmaceutical, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Dizal Pharmaceutical and the tag pipeline.
Shares Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
Shares DZD8586, Dizal Pharmaceutical, Chronic lymphocytic leukaemia.
Shares Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Venetoclax, Chronic lymphocytic leukaemia and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/